🇺🇸 BMRN — BioMarin Pharmaceutical Inc.

Salud Compra
← Volver

Precio actual

56,03 USD

Máx. histórico

149,13

4127 días

Caída desde máximo

-62,43%

Rango 52 semanas

49,26 – 70,98

Variación hoy

-0,16%

Cierre anterior

56,12

Rango de hoy

55,00 – 56,08

Volumen hoy

2.733.184

Peor caída histórica

-90,58%

01/03/2000 → 27/08/2002

Recuperado en 1960 días

Volatilidad anualizada ⓘ

49,10%

Información
Nombre completo
BioMarin Pharmaceutical Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
3.221
PER ⓘ
150,43 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
91,04 USD (puede no estar actualizado)
Primera cotización
26/07/1999
Precio actualizado
hace 17 horas
Sobre la empresa

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
01/08/2011 31,63 31,89 30,44 30,73 -1,60% 4,58% 1.168.100
29/07/2011 30,89 31,68 29,61 31,23 +6,62% 6,70% 1.855.500
28/07/2011 29,58 29,82 28,81 29,29 -0,88% 3,41% 1.474.600
27/07/2011 30,03 30,15 29,17 29,55 -2,41% 3,26% 917.100
26/07/2011 30,08 30,38 29,80 30,28 +0,66% 1,93% 1.118.600
25/07/2011 30,41 30,41 29,93 30,08 -2,05% 1,58% 516.800
22/07/2011 30,20 30,86 30,10 30,71 +1,42% 2,52% 722.100
21/07/2011 30,01 30,42 29,52 30,28 +1,71% 3,00% 741.400
20/07/2011 30,45 30,45 29,65 29,77 -2,27% 2,63% 1.123.800
19/07/2011 29,75 30,49 29,63 30,46 +3,01% 2,89% 955.400
18/07/2011 29,58 29,69 29,26 29,57 -0,40% 1,45% 801.300
15/07/2011 29,92 29,92 29,35 29,69 -0,60% 1,91% 1.222.000
14/07/2011 29,38 30,06 29,32 29,87 +2,12% 2,52% 1.889.300
13/07/2011 28,95 29,34 28,86 29,25 +1,21% 1,66% 852.700
12/07/2011 28,66 29,00 28,56 28,90 +0,84% 1,54% 1.278.400
11/07/2011 28,49 28,72 28,33 28,66 -0,76% 1,37% 1.919.500
08/07/2011 28,42 29,00 28,42 28,88 +0,56% 2,04% 725.200
07/07/2011 28,25 28,88 28,15 28,72 +2,02% 2,58% 1.077.200
06/07/2011 27,64 28,16 27,60 28,15 +1,30% 2,03% 478.900
05/07/2011 27,70 27,88 27,56 27,79 -0,25% 1,16% 456.400
01/07/2011 27,13 27,90 26,94 27,86 +2,39% 3,54% 711.300
30/06/2011 26,82 27,37 26,75 27,21 +1,49% 2,31% 1.033.600
29/06/2011 26,32 26,99 26,05 26,81 +1,98% 3,57% 1.245.400
28/06/2011 25,65 26,42 25,46 26,29 +2,54% 3,74% 1.470.000
27/06/2011 25,47 25,72 25,25 25,64 +0,35% 1,85% 455.000
24/06/2011 25,74 25,76 25,38 25,55 -0,89% 1,48% 1.116.500
23/06/2011 25,49 25,87 25,13 25,78 +0,23% 2,90% 625.600
22/06/2011 25,76 26,09 25,55 25,72 -0,50% 2,10% 396.200
21/06/2011 25,66 25,99 25,34 25,85 +1,37% 2,53% 1.034.900
20/06/2011 25,61 25,81 25,41 25,50 -0,62% 1,56% 479.300